Key result
Higher IL-6 linked to ~16% greater MACE and mortality risk per SD in type 2 diabetes.
Why the study?
The prospective associations of low-grade inflammation markers IL-6, TNF-α, and hsCRP with MACE and mortality in recently diagnosed type 2 diabetes without prevalent CVD were unclear.
Do elevated levels of low-grade inflammation markers (IL-6, TNF-α, hsCRP) predict major adverse cardiac events and mortality in individuals recently diagnosed with type 2 diabetes without prevalent cardiovascular disease?
Cohort (n=7,630)
Yes
Do elevated levels of low-grade inflammation markers (IL-6, TNF-α, hsCRP) predict major adverse cardiac events and mortality in individuals recently diagnosed with type 2 diabetes without prevalent cardiovascular disease?
Hazard Ratio: 1.16 (95% CI 1.09–1.23)
Low-grade inflammation markers (IL-6 and hsCRP) independently predict MACE and all-cause mortality in recently diagnosed type 2 diabetes patients without prevalent CVD, though the absolute improvement in risk prediction is modest.
Aims This study aimed to investigate the prospective associations of interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), and high-sensitivity C-reactive protein (hsCRP) levels with major adverse cardiac event (MACE) and mortality in individuals recently diagnosed with type 2 diabetes and without prevalent CVD. Methods We included 7630 individuals recently diagnosed with type 2 diabetes (median duration 0.9 years) with a median age of 60 years (44% females). Individuals with prevalent CVD (n=1390) were excluded from the primary analyses modelling Fine-Gray subdistribution hazard regressions accounting for competing risk of non-CVD death and adjusting for classical risk factors (e.g. diabetes duration, smoking, alcohol, physical activity, waist circumference, LDL cholesterol, HbA1c, systolic blood pressure, eGFR, and pharmacological treatment). Subsequently, we evaluated the predictive ability of adding low-grade inflammation to a model containing classical risk factors. Results Median follow-up time was 9 years. A 1-SD increase in log-IL-6 (1.98 pg/mL), log-TNF-α (1.40 pg/mL) and log-hsCRP (3.28 mg/L) was associated with HRs of 1.16 (95% CI 1.09, 1.23), 1.01 (0.95, 1.08), and 1.16 (1.09, 1.25) for MACE and 1.38 (1.31, 1.45), 1.16 (1.10, 1.22), and 1.34 (1.25, 1.43) for all-cause mortality, respectively. Prediction of both MACE and all-cause mortality was slightly improved by adding IL-6 and hsCRP to the model alongside classical risk factor. Conclusions Low-grade inflammation was associated with MACE and all-cause mortality, independently of classical risk factors, in individuals recently diagnosed with type 2 diabetes and without prevalent CVD. Despite improved predictive ability of IL-6 and hsCRP, the absolute improvement was sparse.
No takes yet. Share an insight, caveat, or question.
Domazet et al. (2026) conducted a cohort in type 2 diabetes (n=7,630). Low-grade inflammation (IL-6, TNF-α, hsCRP) vs. Lower levels (per 1-SD increase) was evaluated on Major adverse cardiac event (MACE) (HR 1.16, 95% CI 1.09-1.23). A 1-SD increase in log-IL-6 was associated with an increased risk of MACE (HR 1.16; 95% CI 1.09-1.23) and all-cause mortality in individuals recently diagnosed with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: